CN101125140A - Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect - Google Patents
Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect Download PDFInfo
- Publication number
- CN101125140A CN101125140A CNA2007100711855A CN200710071185A CN101125140A CN 101125140 A CN101125140 A CN 101125140A CN A2007100711855 A CNA2007100711855 A CN A2007100711855A CN 200710071185 A CN200710071185 A CN 200710071185A CN 101125140 A CN101125140 A CN 101125140A
- Authority
- CN
- China
- Prior art keywords
- tumor
- dha
- dihydroartemisinine
- ctx
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002521 artenimol Drugs 0.000 title claims abstract description 151
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 102
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 18
- 230000000694 effects Effects 0.000 title claims description 30
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 title abstract description 3
- 229930016266 dihydroartemisinin Natural products 0.000 title abstract description 3
- 230000003014 reinforcing effect Effects 0.000 title 1
- 229940079593 drug Drugs 0.000 claims abstract description 18
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims abstract description 15
- 239000004037 angiogenesis inhibitor Substances 0.000 claims abstract description 15
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000007787 solid Substances 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract description 3
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 claims description 179
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 230000005747 tumor angiogenesis Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 78
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 abstract description 9
- 229960004191 artemisinin Drugs 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 6
- 229930101531 artemisinin Natural products 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000008859 change Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000000890 drug combination Substances 0.000 description 32
- 239000002904 solvent Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 238000011282 treatment Methods 0.000 description 22
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 20
- 229960004397 cyclophosphamide Drugs 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 15
- 238000011081 inoculation Methods 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 6
- 210000003725 endotheliocyte Anatomy 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 101150030763 Vegfa gene Proteins 0.000 description 5
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930191701 arteannuin Natural products 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- -1 and as seen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000007750 drug combination effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides an application of dihydroartemisinin in the preparation of the drugs to enhance the anti-tumor efficacy of the chemotherapeutic drugs. The pharmaceutical preparation contains preparation allowable pharmaceutical excipients or carriers. The form of the preparation is solid preparation. The pharmaceutical preparation provided by the present invention can enhance the anti-tumor efficacy of the chemotherapeutic drugs and can be used in the adjuvant therapy during the tumor chemotherapy process. The present invention takes the theory that the angiogenesis inhibitor can change the micro-environment of tumor as the background, studies and clarifies the function and the mechanism that the effective monomer in the traditional Chinese medicine can enhance the anti-tumor efficacy of the chemotherapy drugs, provides a pharmacological basis for the development of the new usages of the artemisinin drugs and provides an important basis for the development of the new clinical values of the angiogenesis inhibitor, so the present invention is a new research direction for the development of the theory of traditional Chinese medicine.
Description
Technical field
The invention belongs to medicinal usage, relate to the medicinal usage of dihydroartemisinine aspect the enhancing chemotherapy medicine antitumor curative effect.
Background technology
Malignant tumor is to threaten one of the most serious disease of human health, and the main cause of its treatment failure is that tumor cell produces drug resistance to chemotherapeutics.Malignant tumor produces drug resistance except cancerous cell makes a variation by the light of nature to chemotherapeutics, and another major reason is that tumor tissues microenvironment 26S Proteasome Structure and Function is unusual.The mechanism that this unusual microenvironment forms is not illustrated as yet fully, it is generally acknowledged with tumor tissues in new vessels 26S Proteasome Structure and Function major defect, organize factors such as high and low oxygen environment of internal clearance liquid voltage rise and acidosis relevant.Recent years, angiogenesis inhibitor is as the sensitizer paid more and more attention of chemotherapeutics, and fruitful in the treatment kinds of tumors.Some clinical researches show, angiogenesis inhibitor can suppress endotheli ocytosis and obviously suppress growth of tumor and transfer by specificity, its Combination chemotherapy makes the treatment of nonsmall-cell lung cancer (NSCLC) be expected to break away from pining down of " bottle-neck zone ", might become the standard care scheme of advanced NSCLC.
Angiogenesis inhibitor is not only that as the reasonable part of chemotherapeutic sensitizer chemotherapeutics and angiogenesis inhibitor can damage the different ingredient of tumor tissues: tumor cell and endotheliocyte, and angiogenesis inhibitor can change unusual structure of tumor vessel and function, thereby strengthens the therapeutic effect of chemotherapeutics.At first, angiogenesis inhibitor can improve the state of tumor vessel structure disturbance, seepage, reduces interstitial liquid pressure in the tumor, increases drug conveying to inside tumor, and tumor remission histanoxia will make chemotherapy effect strengthen greatly like this.Secondly, angiogenesis inhibitor can stop tumor cell in chemotherapy quick recovery later.Although chemotherapy or radiotherapy can make most of tumor occur disappearing, owing to the serious adverse reaction of chemotherapeutics or radiotherapy has limited its prolonged application.Treatment finishes the back tumor cell can recover apace, breed, and tumor cell again growth rate do not reduce along with the increase of chemotherapy or radiotherapy number of times.Therefore tumor regression does not have the life that really prolongs patient, and Hudis has proposed to implement the feasible solution of angiogenesis inhibitor treatment between the chemotherapy withdrawal time, and the oxygen and the nutrition that are provided by adjacent blood vessel still are provided with the quick propagation again of blocking tumor cell.Once more, angiogenesis inhibitor can strengthen the lethal effect of chemotherapeutics to endotheliocyte, chemotherapeutics not only has direct lethal effect to endotheliocyte during new vascularization, and functional, the great-hearted endotheliocyte of those bone marrow deriveds also had lethal effect, this class cell comprises endothelial progenitor cells, CD54
+Mononuclear cell etc.Endothelial progenitor cells can be divided into sophisticated endotheliocyte, plays a significant role in angiogenesis; CD54
+The cradle that mononuclear cell and other bone marrow like cell groups are angiogenesiss.The low dose of rhythmicity therapeutic modality of chemotherapeutics can the direct killing endotheliocyte, suppresses the endothelial progenitor cells in the blood circulation.These most of endothelial cells can secretion of VEGF, and therefore chemotherapeutics and some are that the drug combination of target spot can be brought into play therapeutic effect collaborative or that add up with VEGF in therapeutic process.Clinical studies show, low dose of rhythmicity treatment of chemotherapeutics and angiogenesis inhibitor share for a long time can bring into play tangible antitumous effect.
Arteannuin (artemisinin) is the sesquiterpene lactones with new structure that China scientist proposed from feverfew Herba Artemisiae annuae (Artemisia annua Linn) first in 1971, and it has very good malaria effect.Dihydroartemisinine (characteristics such as dihydroartemisinin is the intravital main active metabolite of artemisinin-based drug DHA), compares with arteannuin, has good water solubility, and the malaria curative effect is stronger.This seminar early-stage Study shows that artemisinin-based drug can significantly suppress the expression of VEGF among human ovarian cancer transplanted tumor in nude mice tissue and pernicious blood tumor cell strain K562, the RPMI8226, has clear and definite antineoplastic vascular nucleus formation.
The arteannuin dihydroartemisinine
Summary of the invention
This dihydroartemisinine that provides that makes eye bright is preparing the application that strengthens in the chemotherapy medicine antitumor curative effect medicine.Promptly strengthen chemotherapeutics in the effect aspect the antitumor curative effect as a kind of target tumor angiogenesis inhibitor.The molecular formula of described dihydroartemisinine is C
15H
24O
5
Drug prepared of the present invention is an antineoplastic chemotherapy medicine.Contain preparation allowable pharmaceutical excipients or carrier.The dosage form of described medicine is a solid preparation.Administering mode is an oral administration.
The present invention has the following advantages:
(1) dihydroartemisinine is the most representative medicine in the traditional artemisinin-based antimalarial drug, be used for the malaria treatment, characteristics of the present invention are to propose dihydroartemisinine strengthens chemotherapy medicine antitumor as a kind of target tumor angiogenesis inhibitor therapeutic effect first all the time.Malignant tumor is to threaten one of the most serious disease of human health, and chemotherapy will be the main means of oncotherapy, and dihydroartemisinine can be by the blocking-up tumor-blood-vessel growth in oncotherapy, and it is indeterminate to overcome the chemotherapeutics targeting, the deficiency that side effect is bigger.Therefore, combined chemotherapy enhancing antineoplaston effect will obtain important application.
(2) the present invention provides pharmacodynamics and Its Mechanisms foundation thereof for the dihydroartemisinine exploitation becomes the chemotherapeutics sensitizer, has the value with artemisinin-based drug exploitation becoming neoplasm targeted therapy medicine.
(3) the present invention tentatively inquires into the dosage regimen research that dihydroartemisinine strengthens chemotherapy medicine antitumor curative effect, and rationalizing administration for clinical Combination chemotherapy provides the pharmacology foundation.
Description of drawings
Fig. 1 a is dihydroartemisinine (DHA) and cyclophosphamide (CTX) combined treatment I tumor growth curve.
Fig. 1 b is DHA and CTX combined treatment II tumor growth curve.
Fig. 2 a is DHA and CTX combined treatment I tumor stereogram.
Fig. 2 b is DHA and CTX combined treatment II tumor stereogram.
Fig. 3 is the influence of DHA combined with CT X to the tumor-bearing mice tumor weight
Fig. 4 a is that DHA and CTX combined treatment I mouse lung are organized the metastasis stereogram.
Fig. 4 b is that DHA and CTX combined treatment II mouse lung are organized the metastasis stereogram.
Fig. 5 a is DHA and CTX combined treatment I tumor tissues vegf expression.
Fig. 5 b is DHA and CTX combined treatment II tumor tissues vegf expression.
Fig. 6 is the influence of DHA to the LLC cell proliferation.
Fig. 7 induces the apoptotic morphological observation of LLC for DHA.
Fig. 8 a, 8b are that DHA induces the apoptotic flow cytometry quantitative analysis of LLC.
Fig. 9 is the influence of DHA to LLC cell KDR/flk-1 protein expression.
The specific embodiment
The present invention is further described with accompanying drawing in conjunction with specific embodiments.Should be understood that these embodiment only are used for illustration purpose, and be not used in the restriction scope of the invention.With regard to mechanism of action, dihydroartemisinine is applicable to that all rely on the solid tumor (as gastric cancer, hepatocarcinoma, intestinal cancer and breast carcinoma etc.) that blood supply could be grown, and the treatment of neoplastic hematologic disorder (leukemia, multiple myeloma etc.).
Embodiment 1: dihydroartemisinine strengthens the therapeutical effect of cyclophosphamide to Lewis lung cancer growth and transfer
Test material: dihydroartemisinine tablet (Zhejiang Holley South Lake pharmaceutical Co. Ltd), LLC (LewisLung Carcinoma) cell strain (Chinese Academy of Sciences's Shanghai RESEARCH ON CELL-BIOLOGY provides), 100 of C57BL/6 mices, male, body weight 20 ± 2g, 6～8 ages (Chinese Academy of Sciences's Shanghai Experimental Animal Center provides) in week, SABC Elivision
TMPlus wide spectrum test kit (KIT-9901/9902/9903) (Foochow steps neoplasm technology company limited), mouse-anti people VEGF monoclonal antibody (Santa Cruz company).
Method:
(1) Lewis lung cancer growth and metastasis model are set up and dosage regimen
Cultivate mice LLC cell with the DMEM culture fluid that contains 10% calf serum, in 37 ℃, 5%CO
2Hatch in the cell culture incubator, go down to posterity after waiting to cover with the 70-90% area.The trophophase cell of taking the logarithm is adjusted cell concentration to 1 * 10 with serum-free medium
7Ml
-1, 6-8 week male C57BL/6 mouse back subcutaneous vaccination in age, 0.2ml/, totally two.Treat that tumor grows to 500mm
3Size is put to death mice, and aseptic condition takes out tumor piece and cutting down into about 1mm
3Size is inoculated into new 6-8 male C57BL/6 mice right fore oxter in age in week, totally 100 with the trocar.
Be divided into 10 groups after the inoculation at random, 10 every group, begin the administration time difference by cyclophosphamide, use two dosage regimens:
Dosage regimen I: solvent control group normal saline every day is irritated stomach, and dihydroartemisinine begins administration, every day 1 time, continuous 25 times next day after inoculation; Cyclophosphamide after inoculation the 5th day the beginning administration, the next day 1 time, continuous 5 times.Referring to table 1.
Dosage regimen II, solvent control group normal saline every day irritate stomach, and dihydroartemisinine begins administration, every day 1 time, continuous 25 times next day after inoculation; Cyclophosphamide after inoculation the 7th day the beginning administration, the next day 1 time, continuous 5 times.Referring to table 2.
Table 1. dihydroartemisinine strengthens cyclophosphamide to Lewis lung cancer therapeutical effect zoopery dosage regimen I
| Group | Number of animals (only) | Dosage * administration number of times | |
| DHA(mg/kg，qd， ig) ×25 | CTX(mg/kg，qod， ip) ×5 | ||
| Solvent control DHA CTX (d5-13) DHA+CTX (d5-13) DHA+CTX (d5-13) DHA+CTX (d5-13) | 10 10 10 10 10 10 | - 100 - 50 100 200 | - - 50 50 50 50 |
Table 2. dihydroartemisinine strengthens cyclophosphamide to Lewis lung cancer therapeutical effect zoopery dosage regimen II
| Group | Number of animals (only) | Dosage * administration number of times | |
| DHA(mg/kg，qd， ig) ×25 | CTX(mg/kg，qod， ip) ×5 | ||
| Solvent control DHA CTX (d7-15) DHA+CTX (d7-15) DHA+CTX (d7-15) DHA+CTX (d7-15) | 10 10 10 10 10 10 | - 100 - 50 100 200 | - - 50 50 50 50 |
Two treatment sequences all behind last administration 24h, are put to death mice, take out the tumor piece, and it is liquid-solid fixed to get the Bouin of pulmonary ' s.
(2) toxic and side effects of gross tumor volume variation and medicine
Observe ordinary circumstance and the growth of xenografted situation of mice during the administration, gross tumor volume of per 3 days mensuration.Assay method is for using vernier caliper measurement tumor major axis (a), minor axis (b), according to formula V=0.5ab
2Calculate gross tumor volume, draw the gross tumor volume growth curve, measure the mice body weight simultaneously.After mice is put to death, cut open and get tumor tissues and weigh, and calculate tumour inhibiting rate: tumour inhibiting rate=1-(the average tumor weight of the average tumor weight/matched group of medication group) * 100%.
(3) therapeutical effect that the tumor lung is shifted
Treatment finishes the back and puts to death mice, cuts open to get lung tissue and be fixed in Bouin ' s liquid, detects lung surface tumours metastasis behind the 24h, and it is yellow that lung tissue is, the neoplasm metastasis kitchen range protuberance that is white in color.
(4) synergism evaluation criterion
Drug combination effect An Jinshi formula is estimated: q=Ea
+B/ (Ea+Eb-EaEb), wherein Ea
+B is the suppression ratio that two medicines share, and Ea and Eb are the suppression ratio of each prescription time spent, represents that two medicines have share antagonism when q＜1.15, and q＞1.15 o'clock represent that two medicines have synergism.
(5) immunohistochemistry
Above-mentioned tumor tissues takes out the back and fixes with paraformaldehyde, makes the thick paraffin section of 5 μ m after routine is handled, and back SABC, step step the instant second filial generation SABC Elivision of neoplasm technology company limited by Foochow
TMThe operating instruction that provides in the plus reagents for spectrometry box is carried out.The DAB colour developing, gradient ethanol dehydration, neutral gum mounting.The one anti-mouse-anti people VEGF monoclonal antibody (dilution in 1: 50) that adopts, negative control group adopts PBS to replace specificity one anti-.With the xanchromatic strong and weak degree of palm fibre is observation index.
The result
(1) suppresses tumor growth
In Mice Bearing Lewis Lung Cancer transplanted tumor animal model, tumor growth rate of each group of dihydroartemisinine commissural arch phosphamide medication slowly (Fig. 1 a, 1b), treatment finish the back tumor weight than the solvent control group obviously reduce (p＜0.05) (Fig. 2 a, b).Dihydroartemisinine commissural arch phosphamide has therapeutical effect preferably to Lewis lung cancer: by dosage regimen I, 50mg/kgDHA+50mg/kgCTX (d5-13) administration group, 100mg/kgDHA+50mg/kgCTX (d5-13) administration group, the average tumor of 200mg/kgDHA+50mg/kgCTX (d5-13) administration group heavily are respectively 1.33 ± 1.02g, 0.84 ± 0.48g, 0.65 ± 0.45g; The average tumor of three dosage groups heavy with the solvent control group (2.69 ± 1.62g), single with the dihydroartemisinine group (1.67 ± 1.22g), singly organize with cyclophosphamide (d5-13) that (2.16 ± 1.06g) compare and all are obvious inhibition (p＜0.05).By dosage regimen II, 50mg/kgDHA+50mg/kgCTX (d7-15) administration group, 100mg/kgDHA+50mg/kgCTX (d7-15) administration group, the average tumor of 200mg/kgDHA+50mg/kgCTX (d7-15) administration group heavily are respectively 1.13 ± 0.51g, 0.49 ± 0.28g, 0.45 ± 0.22g, the average tumor of three dosage groups heavy with the solvent control group (2.69 ± 1.62g), single with the dihydroartemisinine group (1.67 ± 1.22g), singly organize with CTX (d7-15) that (1.94 ± 0.69g) compare and all are more obvious inhibition (p＜0.05).Show that dihydroartemisinine can strengthen the therapeutical effect of cyclophosphamide to Lewis lung cancer really.While is in the dihydroartemisinine and the cyclophosphamide combination group of same dose, because the time point different table of administering drug combinations reveals the inhibiting difference of tumor growth, 100mg/kgDHA+50mg/kgCTX (d5-13, dosage regimen I) tumor weight and 100mg/kgDHA+50mg/kgCTX (d7-15, dosage regimen II) tumor weight is compared with the tumor-inhibiting action of dosage regimen II more obvious, same 200mg/kgDHA+50mg/kg CTX (d5-13, dosage regimen I) tumor weight and 200mg/kgDHA+50mg/kgCTX (d7-15, dosage regimen II) tumor weight is compared with the tumor-inhibiting action of dosage regimen II more obvious (p＜0.05) (Fig. 3, table 3).
Among Fig. 1 a: ● the solvent control group, zero DHA (100mg/kg) is single with group, ▲ CTX (50mg/kg, d5-13) single with group, △ DHA (50mg/kg)+CTX (50mg/kg, d5-13) drug combination group, ■ DHA (100mg/kg)+CTX (50mg/kg, d5-13) drug combination group, DHA (200mg/kg)+CTX (50mg/kg, d5-13) drug combination group.
Among Fig. 1 b: ● the solvent control group, zero DHA (100mg/kg) is single with group, ▲ CTX (50mg/kg, d7-15) single with group, △ DHA (50mg/kg)+CTX (50mg/kg, d7-15) drug combination group, ■ DHA (100mg/kg)+CTX (50mg/kg, d7-15) drug combination group, DHA (200mg/kg)+CTX (50mg/kg, d7-15) drug combination group.
Among Fig. 2 a: (A) solvent control group, (B) DHA (100mg/kg) is single with group, (C) CTX (50mg/kg, d5-13) single with group, (D) DHA (50mg/kg)+CTX (50mg/kg, d5-13) drug combination group, (E) DHA (100mg/kg)+CTX (50mg/kg, d5-13) drug combination group, (F) DHA (200mg/kg)+CTX (50mg/kg, d5-13) drug combination group.
Among Fig. 2 b: (A) solvent control group, (B) DHA (100mg/kg) is single with group, (C) CTX (50mg/kg, d7-15) single with group, (D) DHA (50mg/kg)+CTX (50mg/kg, d7-15) drug combination group, (E) DHA (100mg/kg)+CTX (50mg/kg, d7-15) drug combination group, (F) DHA (200mg/kg)+CTX (50mg/kg, d7-15) drug combination group.
Among Fig. 3: (A) solvent control group, (B) DHA (100mg/kg) is single with group, (C) CTX (50mg/kg, d5-13) single with group, (D) DHA (50mg/kg)+CTX (50mg/kg, d5-13) drug combination group, (E) DHA (100mg/kg)+CTX (50mg/kg, d5-13) drug combination group, (F) DHA (200mg/kg)+CTX (50mg/kg, d5-13) drug combination group, (G) CTX (50mg/kg, d7-15) single with group, (H) DHA (50mg/kg)+CTX (50mg/kg, d7-15) drug combination group, (I) DHA (100mg/kg)+CTX (50mg/kg, d7-15) drug combination group, (J) DHA (200mg/kg)+CTX (50mg/kg, d7-15) drug combination group.
(2) synergistic therapeutic action
Estimate the therapeutic alliance effect that dihydroartemisinine and cyclophosphamide share according to the Jin Shi formula, single tumour inhibiting rate with 100mg/kg dihydroartemisinine group (DHA) is 37.75%, beginning in the 5th day single tumour inhibiting rate with 50mg/kg cyclophosphamide (d5-13) group in inoculation back is 19.76%, the tumour inhibiting rate of combination group 100mg/kgDHA+50mg/kgCTX (d5-13) is 68.89%, and getting the q value is 1.38; Beginning in the 7th day single tumour inhibiting rate with 50mg/kg cyclophosphamide (d7-15) group in inoculation back is 27.97%, the tumour inhibiting rate of combination group 100mg/kgDHA+50mg/kgCTX (d7-15) is 81.71%, getting the q value is 1.48, show and under two treatment sequences, share dihydroartemisinine and cyclophosphamide all has good synergism, and to begin to share the synergism of cyclophosphamide (dosage regimen II) on the 7th day better to inoculate the back.
(3) toxic and side effects of medicine
During the medication, it is movable good that each organizes tumor-bearing mice, do not see special untoward reaction, and none example is dead.Medication after 25 days solvent control group and single tumor body weight of going with dihydroartemisinine (100mg/kg) be respectively 22.05 ± 1.91g, 22.15 ± 1.59g, it is 22.55 ± 2.32g that the 5th day beginning list in inoculation back goes the tumor body weight with cyclophosphamide (50mg/kg) group, cyclophosphamide is beginning in the 5th day and 50mg/kg after inoculation, 100mg/kg, the mice of respectively organizing that the 200mg/kg dihydroartemisinine share goes the tumor body weight to be respectively 21.89 ± 1.47g, 20.72 ± 0.89g, 21.58 ± 1.17g, it is 22.82 ± 2.17g that the 7th day beginning list in inoculation back goes the tumor body weight with cyclophosphamide (50mg/kg) group, and cyclophosphamide is beginning in the 7th day and 50mg/kg after inoculation, 100mg/kg, the mice of respectively organizing that the 200mg/kg dihydroartemisinine share goes the tumor body weight to be respectively 22.03 ± 1.32g, 21.21 ± 0.58g, 21.80 ± 1.00g.Relatively go tumor mice body weight, each treatment group and solvent control group all do not have significant difference (p＞0.05, table 3).
Table 3, dihydroartemisinine commissural arch phosphamide go the influence of tumor body weight to tumor-bearing mice tumor weight and mice
| Group | Number of animals (only) | Dosage * administration number of times | Go tumor body weight (g) | Tumor heavy (g) | Tumour inhibiting rate (%) | |
| DHA( mg/kg， qd，ig) ×25 | CTX(mg/ kg，qod， ip) ×5 | |||||
| Solvent control DHA CTX (d5-13) DHA+CTX (d5-13) DHA+CTX (d5-13) DHA+CTX (d5-13) CTX (d7-15) DHA+CTX (d7-15) DHA+CTX (d7-15) DHA+CTX (d7-15) | 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 | -- 100 - 50 100 200 - 50 100 200 | -- - 50 50 50 50 50 50 50 50 | 22.05±1.91 22.15±1.59 22.55±2.32 21.89±1.47 20.72±0.89 21.58±1.17 22.82±2.17 22.03±1.32 21.21±0.58 21.80±1.00 | 2.69±1.62 1.67±1.22 ** 2.16±1.06 1.33±1.02 **▲▲▲ 0.84±0.48 ***#▲▲▲ 0.65±0.45 ***##▲▲▲ 1.94±0.69 1.13±0.51 **▲▲▲ 0.49±0.28 **##▲▲▲ 0.45±0.22 **##▲▲▲ | 37.75 19.76 50.54 68.89 75.93 27.97 58.00 81.71 84.60 |
*, p＜0.05;
*, p＜0.01vs solvent control.
#, p＜0.05;
##, p＜0.01vs DHA.
▲ ▲, p＜0.01;
▲ ▲ ▲, p＜0.001vs CTX.
(4) influence that the tumor-bearing mice lung is shifted
In subcutaneous transplantation tumor model, find that solvent control group mice major part spontaneous lung occurs and shifts, single have decline in various degree with DHA, CTX group lung surface metastasis number than the solvent control group, the treatment of dihydroartemisinine commissural arch phosphamide then can suppress the tumor spontaneous lung fully and shift (Fig. 4 a, b, table 4).
The influence that table 4 dihydroartemisinine commissural arch phosphamide shifts tumor-bearing mice tumor spontaneous lung
| Group | Dosage * administration number of times | Shift the generation ratio | The mean transferred kitchen range | |
| DHA(mg/kg，qd，ig) ×25 | CTX(mg/kg，qod，ip) ×5 | |||
| Controi DHA CTX(d5-13) DHA+CTX(d5-13) DHA+CTX(d5-13) DHA+CTX(d5-13) CTX(d7-15) DHA+CTX(d7-15) DHA+CTX(d7-15) DHA+CTX(d7-15) | -- 100 - 50 100 200 - 50 100 200 | -- -- 50 50 50 50 50 50 50 50 | 8/10 4/10 4/10 0/10 0/10 0/10 4/10 0/10 0/10 0/10 | 10.1 1.1 1.3 0 0 0 1.0 0 0 0 |
Among Fig. 4 a: (A) solvent control group, (B) DHA (100mg/kg) is single with group, (C) CTX (50mg/kg, d5-13) single with group, (D) DHA (50mg/kg)+CTX (50mg/kg, d5-13) drug combination group, (E) DHA (100mg/kg)+CTX (50mg/kg, d5-13) drug combination group, (F) DHA (200mg/kg)+CTX (50mg/kg, d5-13) drug combination group.
Among Fig. 4 b: (A) solvent control group, (B) DHA (100mg/kg) is single with group, (C) CTX (50mg/kg, d7-15) single with group, (D) DHA (50mg/kg)+CTX (50mg/kg, d7-15) drug combination group, (E) DHA (100mg/kg)+CTX (50mg/kg, d7-15) drug combination group, (F) DHA (200mg/kg)+CTX (50mg/kg, d7-15) drug combination group.
(5) vegf protein is expressed in the dihydroartemisinine downward modulation tumor tissues
Immunohistochemistry detects the expression of tumor tissues vegf protein, judges the variation of vegf expression amount in the tumor cell with pale brown color power in the cell.The result shows, the solvent control group shows as to be compared with the solvent control group to medium pale brown color by force, the dihydroartemisinine list with group and dihydroartemisinine obviously weaken with the interior pale brown color of each tumor cell of organizing of cyclophosphamide combined treatment (Fig. 5 a, b).(A) solvent control group among Fig. 5 a, (B) DHA (100mg/kg) is single with group, (C) CTX (50mg/kg, d5-13) single with group, (D) DHA (50mg/kg)+CTX (50mg/kg, d5-13) drug combination group, (E) DHA (100mg/kg)+CTX (50mg/kg, d5-13) drug combination group, (F) DHA (200mg/kg)+CTX (50mg/kg, d5-13) drug combination group.(A) solvent control group among Fig. 5 b, (B) DHA (100mg/kg) is single with group, (C) CTX (50mg/kg, d7-15) single with group, (D) DHA (50mg/kg)+CTX (50mg/kg, d7-15) drug combination group, (E) DHA (100mg/kg)+CTX (50mg/kg, d7-15) drug combination group, (F) DHA (200mg/kg)+CTX (50mg/kg, d7-15) drug combination group.
Embodiment 2: the external evoked Lewis lung cancer of dihydroartemisinine (LLC) apoptosis and downward modulation vegf receptor KDR/flk-1 express
Dihydroartemisinine: Guilin pharmaceutical factory is so kind as to give
Method:
(1) mtt assay detects cell proliferation
5 * 10
4Ml
-1The LLC cell inoculation is in 96 orifice plates, and as solvent control, behind variable concentrations dihydroartemisinine effect 48h, mtt assay detects, and measures absorbance (A with microplate reader under the 570nm wavelength with DMSO
570nm) value, calculate cell proliferation rate, cell proliferation rate (%)=experimental group A
570nm/ solvent control group A
570nm* 100%.Adopt IC
50Software for calculation calculates the IC that dihydroartemisinine suppresses the LLC cell proliferation
50Value is with the confidence interval of SPSS10.0 statistical software calculating 95%.
(2) morphologic detection apoptosis
The LLC cell inoculation behind the dihydroartemisinine effect 48h of adding variable concentrations, washes twice with serum-free medium in 24 orifice plates, adds acridine orange 100mgL
-1With bromination second pyridine 100mgL
-1The dyed blended 5min in the darkroom, observation of cell form under the fluorescence inverted microscope.
(3) cells were tested by flow cytometry apoptosis rate and cell cycle
Behind the LLC cell process dihydroartemisinine effect 48h, centrifugal collection is cleaned 2 times through PBS, adjusts cell number to 1 * 10
6ML
-1, slowly splash into 70% ice-cold ethanol fixed cell then, to put 4 ℃ and spend the night, fixed cell adds 50mgL through PBS centrifuge washing 2 times
-1Propidium iodide, 0.1%Triton-X100,37gL
-1EDTA, 50mgL
-1Rnase A, lucifuge is carried out DNA dyeing 30min under the room temperature, crosses 300 order nylon mesh screens, and the up flow type cell instrument is measured in the 24h.Adopt Cell Quest 3.1f software (U.S. Becton Dickinson) to obtain rectangular histogram, ModFit 3.0 softwares (U.S. Becton Dickinson) calculate apoptosis rate and the analysis of cells cycle distributes mutually.
(4) expression of Western-blot quantitative analysis KDR/flk-1
The LLC cell behind the dihydroartemisinine effect 48h of variable concentrations, centrifugal collection, cell lysis extracts albumen, measures protein concentration with the Bradford method, carries out electrophoresis on 12%SDS-PAGE, total protein 50 μ g on each swimming lane.Protein band is transferred on the pvdf membrane behind the electrophoresis, film seals 1h with the TPBS room temperature that contains 5% defatted milk powder, 4 ℃ of placements of mouse-anti people flk-1 polyclonal antibody (dilution in 1: 500) are spent the night, wash film through TPBS, two anti-room temperature effect 1h of horseradish peroxidase-labeled (dilution in 1: 5000), TPBS washes film, adopts the ECL method that target stripe is detected.Adopt the eluting of same film by antibody, the protein band to β-actin detects again, as confidential reference items.
The result:
(1) suppresses the LLC cell proliferation
The MTT experimental analysis shows, handle 48h with dihydroartemisinine after, the LLC cell proliferation is obviously suppressed, and increases its suppression ratio with drug level and be and increase progressively trend, dihydroartemisinine suppresses the IC of LLC cell proliferation
50Value is 53.14 μ molL
-1, 95% confidence interval is 48.69-58.18 μ molL
-1Above result shows that dihydroartemisinine has obvious inhibitory action to LLC propagation, and is concentration dependent, and referring to Fig. 6, DHA is to the half-inhibition concentration (IC of LLC cell proliferation among the figure
50)=53.14 μ molL
-1, 95% confidence interval is 48.69-58.18 μ molL
-1
(2) dihydroartemisinine is induced the apoptotic morphological observation of LLC
The LLC cell is after the two dyeing of acridine orange/bromination second pyridine, and as seen, solvent control group nucleus presents the uniform green fluorescence of density under the fluorescence microscope, show as Normocellular dyeing characteristic, and behind dihydroartemisinine effect 48h, cell presents typical apoptosis morphological change such as the coagulation of chromatin height, marginalisation etc., the visible fluorescent orange of Fluirescence observation strengthens, be compact massive and distribute, and apoptotic body occurs, referring to Fig. 7, among Fig. 7: (A) solvent control group, (B) DHA 20 μ molL
-1, (C) DHA 40 μ molL
-1, (D) DHA 80 μ molL
-1
(3) the apoptotic streaming quantitative analysis of the inductive LLC of dihydroartemisinine
Through flow cytometry analysis, show that according to PI fluorescence rectangular histogram the LLC cell is through 20 μ molL
-1Behind the dihydroartemisinine effect 48h, percentage of cell apoptosis is significantly increased, through 40,80 μ molL
-1Behind the dihydroartemisinine effect 48h, the hypodiploid peak of apoptotic cell has appearred before the G1 peak representing, apoptosis rate rise to 9.82% and 13.86% respectively (Fig. 8 a, b).Wherein among Fig. 8 a: (A) solvent control group, (B) DHA20 μ molL
-1, (C) DHA 40 μ molL
-1, (D) DHA 80 μ molL
-1
(4) dihydroartemisinine suppresses the expression of LLC cell KDR/flk-1
The LLC cell extracts albumen after the variable concentrations dihydroartemisinine is handled, the Western-blot method detects the proteic expression of KDR/flk-1 in the cell, and the result shows that along with the increase of drug level, the proteic expression of cell KDR/flk-1 descends successively.40,80 μ molL
-1The expressing quantity of dihydroartemisinine concentration group cell KDR/flk-1 is reduced to 33.8% and 12.6% of solvent control group respectively, compares with the solvent control group to have significant difference (p＜0.001), and the result is referring to Fig. 9.
Claims (6)
1. the application of dihydroartemisinine in preparation enhancing chemotherapy medicine antitumor curative effect medicine, the molecular formula of described dihydroartemisinine is C
15H
24O
5
2. the application of dihydroartemisinine according to claim 1 in preparation enhancing chemotherapy medicine antitumor curative effect medicine is characterized in that: dihydroartemisinine is as the application of a kind of target tumor angiogenesis inhibitor in preparation enhancing chemotherapy medicine antitumor curative effect medicine.
3. the application of dihydroartemisinine according to claim 1 in preparation enhancing chemotherapy medicine antitumor curative effect medicine, it is characterized in that: drug prepared also contains preparation allowable pharmaceutical excipients or carrier.
4. the application of dihydroartemisinine according to claim 1 in preparation enhancing chemotherapy medicine antitumor curative effect medicine, it is characterized in that: drug prepared is an antineoplastic chemotherapy medicine.
5. the application of dihydroartemisinine according to claim 1 in preparation enhancing chemotherapy medicine antitumor curative effect medicine, it is characterized in that: the dosage form of described medicine is a solid preparation.
6. the application of dihydroartemisinine according to claim 5 in preparation enhancing chemotherapy medicine antitumor curative effect medicine, it is characterized in that: the administering mode of described medicine is an oral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100711855A CN101125140B (en) | 2007-09-18 | 2007-09-18 | Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100711855A CN101125140B (en) | 2007-09-18 | 2007-09-18 | Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101125140A true CN101125140A (en) | 2008-02-20 |
| CN101125140B CN101125140B (en) | 2011-04-13 |
Family
ID=39093331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100711855A Expired - Fee Related CN101125140B (en) | 2007-09-18 | 2007-09-18 | Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101125140B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102665711A (en) * | 2009-12-23 | 2012-09-12 | 希格马托制药工业公司 | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents |
| CN101940569B (en) * | 2009-07-07 | 2013-02-13 | 鼎泓国际投资（香港）有限公司 | Medicament composition containing sorafenib, artemisinin and artemisinin derivative and application thereof in preparing medicament for treating cancer |
| CN103948689A (en) * | 2014-04-15 | 2014-07-30 | 西北农林科技大学 | Medicinal composition for treating non-small cell lung cancer and application thereof |
| CN111808117A (en) * | 2018-05-16 | 2020-10-23 | 中国科学院昆明植物研究所 | Artemisinin-anilinoquinazoline D-type derivative, and pharmaceutical composition and application thereof |
| CN112773788A (en) * | 2020-09-29 | 2021-05-11 | 上海市肺科医院 | Application of dihydroartemisinin in preparation of non-small cell lung cancer medicine |
-
2007
- 2007-09-18 CN CN2007100711855A patent/CN101125140B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940569B (en) * | 2009-07-07 | 2013-02-13 | 鼎泓国际投资（香港）有限公司 | Medicament composition containing sorafenib, artemisinin and artemisinin derivative and application thereof in preparing medicament for treating cancer |
| CN102665711A (en) * | 2009-12-23 | 2012-09-12 | 希格马托制药工业公司 | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents |
| CN103948689A (en) * | 2014-04-15 | 2014-07-30 | 西北农林科技大学 | Medicinal composition for treating non-small cell lung cancer and application thereof |
| CN111808117A (en) * | 2018-05-16 | 2020-10-23 | 中国科学院昆明植物研究所 | Artemisinin-anilinoquinazoline D-type derivative, and pharmaceutical composition and application thereof |
| CN112773788A (en) * | 2020-09-29 | 2021-05-11 | 上海市肺科医院 | Application of dihydroartemisinin in preparation of non-small cell lung cancer medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101125140B (en) | 2011-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101125140B (en) | Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect | |
| CN104398526B (en) | The application of triptolide and Celastrol in antineoplastic is prepared | |
| CN109091480A (en) | Cancer composition 10-hydroxycamptothecine and gram azoles are for Buddhist nun's treatment lung cancer and purposes | |
| CN105963637A (en) | Application of combination of cryptotanshinone and curcumin in preparation of drug for treating tumor | |
| CN101721397A (en) | Medical application of 6-shogaol for treating cervical cancer, leukemia and breast cancer | |
| CN109568299A (en) | Ambroxol purposes in preparing tumor chemotherapeutic drug Synergistic preparations | |
| CN103040864B (en) | Medical application of selenium phosphate compound | |
| CN105476996A (en) | Application of curcumin and afatinib for combined treatment of non-small cell lung cancer | |
| CN109453164A (en) | A kind of antitumor combination medicine | |
| CN105769889A (en) | Application of ginsenoside Ro in preparation of antitumor drugs | |
| TWI797426B (en) | Use of chiauranib in treating small cell lung cancer | |
| CN103251585A (en) | Effects and application of artemisinin and its derivative in inhibition of platelet-derived growth factor receptor A | |
| CN104586873A (en) | Application of oroxin A in preparation of medicines for treating cancer | |
| CN101773499A (en) | New applications of tetrahydropalmatine | |
| CN100998805A (en) | Biporia strengthening the body resistance anticancer preparation and its preparation method | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| CN103830288B (en) | Match certain herbaceous plants with big flowers extractive of general flavone and its production and use | |
| CN109106716A (en) | The purposes of the combination of onocerin and fluorouracil in the preparation of antitumor drugs | |
| CN108478557A (en) | Application of the atractylenolide Ⅰ in preparing medicines resistant to liver cancer | |
| CN102357123A (en) | Application of herba dicranostigmae alcohol extract in preparing medicines for resisting melanoma transfer | |
| CN105534966A (en) | Application of gamma-aminobutyric acid as active ingredient for enhancing chemotherapeutic sensitivity | |
| CN100546621C (en) | A kind of new purposes of known drug | |
| CN104892707A (en) | Compound CLCN based on oriented synthesis and application of CLCN to anti-liver cancer drugs | |
| CN101485660B (en) | Anti-tumor use of alpha-(8-quinolinoxy) monosubstituted phthalocyanine zinc | |
| CN110354121A (en) | Application of the Ciclopirox Olamine in preparation tumor and composition of medicine and purposes comprising Ciclopirox Olamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110413 Termination date: 20200918 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |